Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Assets (2016 - 2025)

Cytosorbents (CTSO) has disclosed Current Assets for 14 consecutive years, with $21.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 28.41% year-over-year to $21.3 million, compared with a TTM value of $21.3 million through Sep 2025, up 28.41%, and an annual FY2024 reading of $21.6 million, down 15.95% over the prior year.
  • Current Assets was $21.3 million for Q3 2025 at Cytosorbents, down from $23.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $79.6 million in Q1 2021 and bottomed at $16.6 million in Q3 2024.
  • Average Current Assets over 5 years is $37.1 million, with a median of $25.7 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 112.19% in 2021, then plummeted 55.49% in 2022.
  • Year by year, Current Assets stood at $64.3 million in 2021, then tumbled by 47.5% to $33.8 million in 2022, then fell by 23.87% to $25.7 million in 2023, then decreased by 15.95% to $21.6 million in 2024, then dropped by 1.35% to $21.3 million in 2025.
  • Business Quant data shows Current Assets for CTSO at $21.3 million in Q3 2025, $23.0 million in Q2 2025, and $25.4 million in Q1 2025.